Table 4

Description of the participants for model validation by gender

VariableMaleFemale
ControlCHDControlCHD
(n=99)(n=176)(n=91)(n=70)
Age (year)52.5±9.261.0±10.751.0±7.461.8±10.6
UA (µmol/L)395.3±80.3363.4±97.9297.0±74.3298.5±88.4
TC (mmol/L)4.7±0.84.5±1.14.7±0.74.62±1.2
TG (mmol/L)1.8 (1.2, 2.6)1.7 (1.3, 2.4)1.3 (1.0, 2.0)1.8 (1.4, 2.9)
HDL-C (mmol/L)1.4±0.31.2±0.21.6±0.31.3±0.3
LDL-C (mmol/L)2.9±0.82.5±0.92.9±0.62.6±0.9
apoA (g/L)1.5±0.21.3±0.21.7±0.21.5±0.3
apoB (g/L)0.99±0.241±0.230.93±0.20.97±0.29
Lp(a) (mg/L)188.0 (85.0, 373.0)297.0 (140.0, 433.0)163.0 (81.0, 327.0)248.0 (98.0, 470.0)
HCY (µmol/L)10.3 (8.5, 12.8)14.5 (11.9, 19.0)6.4 (5.3, 7.8)11.6 (9.0, 13.7)
TBil (µmol/L)13.4 (10.7, 16.5)14.2 (11.2, 19.3)10.8 (8.7, 13.1)12.8 (10.4, 17.7)
Dbil (µmol/L)3.0 (2.5, 3.8)3.0 (1.9, 4.3)2.3 (1.9, 2.9)2.2 (1.5, 3.2)
IBil (µmol/L)10.4 (8.1, 13.1)11.0 (8.5, 15.2)8.3 (6.5, 10.4)11.2 (8.4, 14.2)
GGT (IU/L)27.0 (17.0, 47.0)35.0 (22.0, 79.0)18.0 (12.0, 25.0)25.0 (16.0, 44.0)
  • Normally distributed data were presented as means±SD, skewed data were presented as the median (IQR).

  • apoA, apolipoprotein A; apoB, apolipoprotein B; Bil, indirect bilirubin; CHD, coronary heart disease; DBil, direct bilirubin; GGT, γ-glutamyl transpeptidase; HCY, homocysteine; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein(a); TBil, total bilirubin; TC, total cholesterol; TG, triglyceride; UA, uric acid.